Floatz Rating
D30/100
Confidence
Indicative
Sponsor
Chinese University of Hong Kong
Modality
Small molecule
Development Phase
Unknown
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03457961CT.gov Post-market Study of AMPA Receptor Antagonists for Epilepsy Patients in Hong Kong | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Generalized Epilepsy
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Perampanel (this asset) | Chinese University of Hong Kong | Unk | D · 30 |
| Topiramate | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | P4 | BBB |
| Melatonin | All India Institute of Medical Sciences, Bhubaneswar | P4 | BB |
| Clobazam | Lundbeck LLC | P3 | BB |
| Cenobamate | Ono Pharmaceutical Co., Ltd. | P3 | BB |
| Diazepam | Pfizer | P3 | B |
| Opakalim | Biohaven Therapeutics Ltd. | P2/3 | B |
| Npt 2042 | NeuroPro Therapeutics, Inc. | P2 | CCC |
| Fludeoxyglucose | National Institute of Neurological Disorders and Stroke (NINDS) | Unk | D |
+3 more in the Generalized Epilepsy cohort
Other indications for Perampanel
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Epilepsy | — | P4 | BB · 71 |
| Neuralgia | — | P2/3 | BB · 66 |
| Grade II Glioma | — | P4 | B · 61 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Perampanel in Generalized Epilepsy. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/perampanel-generalized-epilepsy
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →